Sign Out
The maximum doses of teneligliptin in clinical studies were 320 mg for a single dose in healthy adult subjects and 80 mg once daily for 7 days for repeated doses in healthy adult subjects. No serious adverse drug events and adverse drug events leading to discontinuation of the study treatment were reported after administration of teneligliptin at the 2 doses.
QT interval prolongation has been reported after administration of this product at a dose of 160 mg once daily (see Precautions and Pharmacology: Pharmacokinetics under Actions).
